 |
 |
 |
|
 |
 |
 |
| |||||||
|
Assessing the Likelihood of Recurrence in Breast Cancer In early stage invasive breast cancer, the evaluation of the likelihood of distant recurrence is based on multiple factors, such as nodal status, tumor size, tumor grade, and ER (estrogen receptor), PR (progesterone receptor), and HER2 status. However, there is a significant unmet need: quantitative, clinically validated predictors of disease recurrence risk that provide significant insight into breast cancer treatment decisions. To help address this unmet need, the research team at Genomic Health® developed a robust assay (Oncotype DX®) that utilizes gene expression profiling to quantitatively assess the likelihood of breast cancer recurrence more precisely and reliably than markers currently available in clinical practice. Oncotype DX is clinically validated to assess the likelihood of distant recurrence in women with newly diagnosed, stage I or II, node-negative, estrogen receptor-positive breast cancer. A recent study has also shown that Oncotype DX may be informative for post-menopausal women with node positive, hormone receptor positive breast cancer. The performance of Oncotype DX exceeds standard measures such as tumor size, tumor grade, and patient age in terms of either predictive power or reproducibility. The Oncotype DX assay is recommended by the Updated ASCO Clinical Guidelines for Use of Tumor Markers in Breast Cancer and the Updated NCCN Clinical Practice Guidelines in Oncology Breast Cancer to predict the risk of recurrence and benefit from chemotherapy in node-negative, ER-positive breast cancer treated with tamoxifen.1,2,3 For a Sample Node Negative Report, please click here. For a Sample Node Positive Report, please click here. |
|
|
|||||
|
|
| © 2008 Genomic Health, Inc. All rights reserved. | | Home | Contact Us | Privacy | Terms and Conditions | |